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Abstract 10 
Perfluorooctane sulfonate (PFOS) found extensive use for over 60 years up until its 11 
restriction in the early 2000s, culiminating in its listing under the Stockholm Convention on 12 
Persistent Organic Pollutants (POPs) in 2009. Efforts to minimise human body burdens are 13 
hindered by uncertainty over their precise origins. While diet appears the principal source for 14 
the majority of western populations, with other pathways like dust ingestion, drinking water, 15 
and inhalation also important contributors; the role played by exposure to PFOS-precursor 16 
compounds followed by in vivo metabolism to PFOS as the ultimate highly stable end-17 
product is unclear. Such PFOS-precursor compounds include perfluorooctane sulfonamide 18 
derivates, e.g. perfluorooctane sulfonamides (FOSAs) and sulfonamidoethanols (FOSEs). 19 
Understanding the indirect contribution of such precursors to human body burdens of PFOS 20 
is important as a significant contribution from this pathway would render the margin of safety 21 
between the current exposure limits and estimates of external exposure to PFOS alone, 22 
narrower than hitherto appreciated. Estimates derived from mathematical modelling studies, 23 
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put the contribution of so-called ―precursor exposure‖ at between 10% and 40% of total 24 
PFOS body burdens. However, there are substantial uncertainties associated with such 25 
approaches. This paper reviews current understanding of human exposure to PFOS, with 26 
particular reference to recent research highlighting the potential of environmental forensics 27 
approaches based on the relative abundance and chiral signatures of branched chain PFOS 28 
isomers to provide definitive insights into the role played by ―precursor exposure‖. 29 
Keywords 30 
Perfluoroalkyl sulfonate, PFOS-precursors, perfluoroalkyl substances, biomonitoring, human 31 
exposure, chirality, isomer, body burdens 32 
 33 
34 
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INTRODUCTION 35 
Perfluoroalkyl substances (PFASs) are a family of synthetic compounds characterised by a 36 
fully fluorinated hydrophobic linear carbon chain, to which are attached different hydrophilic 37 
functional groups (Fromme et al., 2009). These chemicals have been manufactured since the 38 
late 1940s by 3M (3M, 1999) as well as other companies like Dupont, and have been 39 
produced and used in commercial products and industrial processes for over 60 years 40 
(Lindstrom et al., 2011). PFASs possess low molecular polarisability, short C–F bond length, 41 
and large C–F bond binding energy. Such characteristics govern the oil and water repellency, 42 
physical and chemical stability, and surfactant properties of PFASs (Zushi et al., 2012). 43 
These properties mean that PFASs have found wide use in a variety of applications, with 44 
historic production peaking at the end of the 20
th
 century in North America and Europe (Paul 45 
et al., 2009). In an environmental context however, the strong C-F bond means that PFASs 46 
are resistant to thermal, chemical and biological degradation (Kissa, 2001) and are capable of 47 
bioaccumulation and long-range environmental transport, exemplified by their detection in 48 
the Arctic (Chaemfa et al., 2010; Sonne, 2010; Zhao et al., 2012). As a result, PFOS and its 49 
salts, as well as perfluorooctane sulfonyl fluoride (POSF) were in 2009 listed as persistent 50 
organic pollutants (POPs) under the Stockholm Convention (Geneva: Stockholm Convention 51 
Secretariat, 2009). POSF can degrade to PFOS directly or indirectly through chemical or 52 
enzymatic hydrolysis, and hence POSF-derived products can be degraded ultimately to PFOS 53 
(Zhao et al., 2012). 54 
PFAS synthesis routes have been well described by Lehmler et al. (2005). The two main 55 
processes are electro-chemical fluorination (ECF) (3M, 1999), and telomerisation (Schultz et 56 
al., 2003), with PFOS, and PFOS salts synthesised via ECF. It is important to note here that a 57 
number of possible PFOS isomers exist in POSF based mixtures (in which process PFOS 58 
impurities are present between 0.1 and 5% (Paul et al., 2009) due to the nature of the ECF 59 
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process itself). The isomer composition of the commercial PFOS products can be up to 30% 60 
of total PFOS. Moreover, some of these isomers (specifically those that are branched chain) 61 
are chiral, with the result that the environmental fate and behaviour of PFOS may vary 62 
according to its isomeric and enantiomeric composition. 63 
The main applications of PFOS and PFOS derivatives included uses in: inks, varnishes, 64 
waxes, fire-fighting foams, metal plating and cleaning products, coating formulations (for 65 
walls, furniture, carpeting, food packaging), lubricants, water and oil repellents for leather, 66 
paper and textiles (3M, 2000). Before 2003, POSF was used as a raw material for the 67 
synthesis of PFOS (among other perfluorooctane sulphonamide derivates) (Burk et al., 2011). 68 
However, 3M Company replaced PFOS with perfluorobutane sulfonate (PFBS) after 2003, 69 
because the former was considered harmful to the environment (Renner, 2006). 70 
Over the last 15 years, a substantial weight of evidence has emerged concerning 71 
environmental contamination with PFOS, consequent human exposure, and its effects. This 72 
paper reviews this evidence, and summarises recent developments that exploit the chirality 73 
and relative abundance of branched chain PFOS isomers to provide valuable insights into the 74 
environmental fate and behaviour of PFOS and its precursors. 75 
 76 
SOURCES, PRODUCTION AND APPLICATIONS 77 
The history of PFAS production is difficult to portray accurately due to the proprietary nature 78 
of this information (Lindstrom et al., 2011), but the 3M Company was the first main producer 79 
of POSF (an intermediate product for the synthesis of PFOS) with the total cumulative 80 
production estimated to be approximately 96,000 t in the peak years between 1970 and 2002 81 
(Paul et al., 2009). In 2002, the 3M Company discontinued its production; however other 82 
companies commenced manufacture at this point to meet existing market demands, with an 83 
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estimated 1,000 t being produced annually since 2002 (Paul et al., 2009). In addition to the 84 
3M production facilities in the USA, another 6 plants were located in Europe (4 in EU 85 
member states), 6 in Asia (of which 4 were in Japan) and one in South America (Paul et al., 86 
2009). 87 
The main way of synthesising PFASs is ECF. In this process, a straight chain hydrocarbon is 88 
reacted with H and F atoms and electricity to substitute all of the hydrogen atoms with 89 
fluorine (Kissa, 2001). This constitutes the main process of POSF synthesis, generating about 90 
70% of the straight chain product with the remainder comprised of branched and cyclic 91 
isomers. POSF can then be used in a series of reactions via N-methyl and N-ethyl 92 
perfluorooctane sulfonamide (N-MeFOSA and N-EtFOSA) to yield N-methyl and N-ethyl 93 
perfluorooctane sulfonamidoethanols (N-MeFOSE and N-EtFOSE), which historically were 94 
used to produce polymeric materials and phosphate esters respectively, and used on surface 95 
coatings for textiles and paper products (Paul et al., 2009; Olsen et al., 2005, D’Eon and 96 
Mabury, 2011). 97 
The major applications of POSF derivatives have been: (1) in carpets to impart stain and dirt 98 
repellence, (2) in apparel to provide water repellence, (3) in paper and packaging to afford oil 99 
and grease repellence, (4) in performance chemicals such as hydraulic fluids for aviation, and 100 
(5) in aqueous fire-fighting foams (AFFFs). AFFFs are perhaps the most prominent method 101 
of widespread environmental dispersal, with use for oil drilling and military fire-fighting 102 
practice (Paul et al., 2009). 103 
All compounds produced from POSF are widely referred to as ―PFOS equivalents‖ or just 104 
―PFOS‖, due to their collective potential to degrade or transform into PFOS. In contrast, 105 
PFOS itself is extraordinarily stable in the environment, with no known natural mechanism of 106 
degradation. Hence, regulatory bodies have been working to reduce the production and use of 107 
some PFASs (Zushi et al., 2012). The 3M company, together with the US Environmental 108 
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Protection Agency (USEPA) resolved to decrease the production of PFOS and related 109 
compounds between 2000 and 2002 (3M, 2008). At the same time, Significant New Use 110 
Rules (SNUR) were also put in place (2000, 2002, and 2007) in the US, designed to restrict 111 
the production and use of materials that contained PFOS or its various precursors. The EPA 112 
then worked with eight leading chemical companies in the 2010-2015 PFOA Stewardship 113 
Program to reduce emissions and residual content of PFOA and long-chain PFCAs by 95% 114 
by 2010, with the long-term goal to work towards elimination of long-chain PFCAs by 2015 115 
(USEPA, 2010). 116 
Within the EU, PFOS and its derivatives are regulated on the market or only used as a 117 
substance or constituent of preparations listed as permissible in the EU Directive (2006). 118 
Under this directive, PFOS may still be used in applications that are deemed un-substitutable, 119 
including photolithographic processes, photographic coatings, mist suppressants for non-120 
decorative hard chromium (VI), plating/wetting agents in controlled electroplating systems 121 
(pollution prevention and control are required), and hydraulic fluids for aviation. Such 122 
regulation started within the EU in June 2008 (Zushi et al., 2012). 123 
The presence of PFOS in the environment has been attributed to two major sources: direct 124 
and indirect (Armitage et al., 2009; Prevedouros et al., 2006; Paul et al., 2009). Direct sources 125 
are derived from the manufacture and application of PFOS and POSF (Paul et al., 2009). By 126 
comparison, indirect sources are a consequence of chemical reaction impurities or breakdown 127 
of so-called precursors such as N-Me-FOSE and N-Et-FOSE. It has been estimated that 85% 128 
of indirect emissions occur via release from consumer products during use and disposal (3M, 129 
2000). 130 
 131 
HEALTH CONCERNS 132 
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General toxicological findings associated with laboratory animals exposed to PFOS include 133 
hepatomegaly and hepatic peroxisome proliferation, liver, testicular (Leydig cell), and 134 
pancreatic (acinar cell) tumours, reproductive and developmental deficits, neurotoxicity, and 135 
immunotoxicity (DeWitt et al., 2012). 136 
Most of the reported studies concerning PFOS toxicity have been conducted on mice, with 137 
subsequent extrapolation to humans of observed murine effects complicated by interspecies 138 
variability in toxicokinetics. Even gender and ethnic origin can play a role (Kato et al., 2011). 139 
Adverse effects attributed to PFOS in rodents include decreased body weight, increased liver 140 
weight, and a steep dose-response curve for mortality (Seacat et al., 2003), as well as an 141 
increase in hepatocellullar and follicular cell adenomas at high exposure levels (3M, 2002). 142 
Human studies carried out on workers occupationally exposed to PFAS have generally 143 
yielded inconsistent results. While such workers have circulating blood levels of PFAS that 144 
are hundreds of times those of non-occupationally exposed individuals (Olsen et al., 2003; 145 
Steenland et al., 2010), it is difficult to determine conclusive results in these studies (either 146 
positive or negative) because sample populations are small, historical exposure levels are 147 
uncertain, individuals often have had simultaneous exposures to other compounds, and they 148 
may have pre-existing conditions that complicate evaluations (Fletcher et al., 2013). 149 
Compared to PFOS, studies of PFOA exposed workers are more numerous. Several studies 150 
have shown a positive association between PFOA exposure and cholesterol, which could 151 
have implications for the development of cardiovascular disease. PFOA has also been 152 
associated with elevated uric acid levels, which may in turn lead to hypertension and 153 
cerebrovascular disease (Lindstrom et al., 2011; Olsen et al., 2003; Costa et al., 2009; Sakr et 154 
al., 2007). 155 
Based on the toxicological evidence available to date, chronic exposure guidelines are being 156 
developed for PFOS and PFOA by the USEPA and other jurisdictions for water and food, but 157 
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little has been done thus far for other PFASs. A review of current global guidelines and 158 
regulations can be found in Zushi et al. (2012), and some especially pertinent illustrative 159 
examples are discussed briefly here. The continuing uncertainty surrounding the human 160 
health impacts of PFASs is reflected in the disparity between the values promulgated by 161 
different jurisdictions. The risk from PFOS for human adults has been evaluated as low based 162 
on the Margin of Exposure (MOE), derived from the ratio of the provisional tolerable daily 163 
intakes (pTDI) and the level of intake (Zushi et al., 2012). Fromme et al. (2009) estimated the 164 
average (and high end) daily intake of PFOS and PFOA, including the indirect contribution 165 
from their precursors, as 1.6 (11.0) and 2.9 (12.7) ng/kg bw/day, respectively. These 166 
exposures are comfortably lower than the pTDIs for the general adult population of 100 ng/kg 167 
bw/day for PFOS and 3000 ng/kg bw/day for PFOA, promulgated by the German Federal 168 
Institute for Risk Assessment (BfR) and the UK Committee on Toxicity of Chemicals in 169 
Food, Consumer Products and the Environment (COT) respectively. Moreover, the USEPA 170 
issued provisional short-term health advisories for PFOS (200 ng/L) and PFOA (400 ng/L) in 171 
drinking water, on the assumption that short-term consumption below these levels will 172 
safeguard public health (USEPA, 2009). 173 
In a parallel approach to limit values for external exposure via ingestion of food and water, 174 
the Biomonitoring Commission of the German Federal Environmental Agency used the 95
th
 175 
percentile concentration values of two German studies (Midasch et al., 2006; Fromme et al., 176 
2007b), to establish reference values for PFOA and PFOS in plasma of children and adults. 177 
These reference values specify a maximum permissible presence of PFOS of 10 µg/L for 178 
children, 20 µg/L for adult females, and 25 µg/L for adult males (Wilhelm et al., 2009). 179 
 180 
HUMAN EXPOSURE 181 
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The first report of the presence of PFOS, PFOA, and other PFASs in samples of human blood 182 
purchased from biological supply companies emerged in 2001 (Hansen et al., 2001), although 183 
the first paper regarding the presence of organofluorine compounds in biological samples 184 
dates from 1968 (Taves, 1968). Since then, a considerable database concerning human 185 
exposure to PFASs has emerged. The following section summarises current understanding of 186 
this topic with particular reference to PFOS. 187 
Human Biomonitoring Data 188 
With respect to human biomonitoring, concentrations of PFAS in human blood (whole blood, 189 
plasma and serum) in the general population have been reviewed recently (Angerer et al., 190 
2011; Fromme et al., 2009) (Table 1). Most human biomonitoring studies are not carried out 191 
on whole blood, but on serum. The first reported concentrations of PFOS in blood were 192 
published by Hansen et al. (2001). This study showed 100% of the blood samples contained 193 
PFOS at concentrations ranging from 6.7 to 81.5 ng/mL. Following this seminal report, 194 
concern about how PFOS enters and remains in the human body increased, leading to the 195 
publication of a number of studies, each based on the analysis of a large number of blood 196 
samples. Amongst the most relevant of these are those of Calafat et al. and Kato et al. 197 
(Calafat et al., 2007a and 2007b; Kato et al., 2011) in the North American population, which 198 
each discuss results from the National Health and Nutrition Examination Surveys (NHANES) 199 
carried out by the US Center for Disease Control and Prevention, and published in the Fourth 200 
National Report on Human Exposure to Environmental Chemicals (CDC 2009; CDC 2013). 201 
In these reports, the presence of a range of chemical contaminants is studied in blood and 202 
urine from the general population of the USA. The PFOS measurements reported in the two 203 
papers from Calafat et al. refer to the NHANES results from 1999-2000 and 2003-2004, and 204 
are based on 1,562 and 2,094 serum samples, with a detection frequency (DF) > 96% for 205 
PFOS in both studies, and geometric means of 21.1 and 20.7 ng/mL respectively. One of the 206 
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studies (Calafat et al., 2007b), also reported that geometric mean PFOS levels declined by 207 
32% between 1999/2000 and 2003/2004. Moreover, the most recent (2007/2008) NHANES 208 
results (Kato et al., 2011), indicate that PFOS concentrations continue to decline (exemplified 209 
by a geometric mean of 13.2 ng/mL). This follows an earlier report (Olsen et al., 2007b) of a 210 
decrease on PFOS levels in human blood in the general American population, from a 211 
geometric mean of 33.1 ng/mL in samples collected in 2000, to 15.1 ng/mL in samples 212 
collected in 2005. A second study (Olsen et al., 2008) based on a large number of human 213 
blood samples (around 600), highlighted that the observed ~60% decline in PFOS was 214 
consistent with its elimination half-life and the time period since the phase-out of POSF by 215 
3M in 2000-2002. Combined, these studies suggest that restrictions on the production and use 216 
of PFOS have led to reductions in human exposure in the US, although it remains in the 217 
environment, wildlife and the US population (CDC, 2009). Other US studies document 218 
similar PFOS concentrations in blood, but can not provide evidence of a temporal trend. 219 
Specifically, Hansen et al. (2001), as well as Olsen et al. (2005), published results in which 220 
median PFOS concentrations were 26.2 and 34.7 ng/mL for samples taken in the late 221 
1990s/early 2000s (exact sampling dates not given) and 1974/1989 respectively. This 222 
apparent increase in human exposure in the immediate aftermath of the 2002 voluntary 223 
cessation of production by 3M, may be attributed to variation in the respective populations 224 
sampled in the two studies. 225 
An important point is that – in line with Taniyasu et al., 2003 - the values in Table 1 include 226 
data for both serum and whole blood. This approach is preferred here to the alternative format 227 
employed by others (e.g. Yeung et al. (2006) and Kannan et al. (2004)) whereby 228 
concentrations in whole blood were converted to concentrations in serum by multiplying 229 
whole blood concentrations by 2, to allow comparison across different studies. This 230 
conversion becomes even more sensitive when analysing PFOS precursors, due to their 231 
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different distribution between serum and blood (Martin et al., 2010). Notwithstanding the 232 
influence of serum versus whole blood basis concentrations, examination of the global 233 
database between 2004 and 2007, reveals some differences in both median and maximum 234 
PFOS concentrations in human blood recorded in different studies shown in Table 1. Likely 235 
causes of these between-study variations in the concentrations of PFOS include: international 236 
variations in use and exposure, as well as variations between sampled populations in lifestyle, 237 
age, ethnicity, and gender (Kato et al., 2011). While such differences in absolute 238 
concentrations of PFOS exist, they are not as marked as those observed for other halogenated 239 
persistent organic pollutants like polybrominated diphenyl ethers (Hites, 2004). 240 
Table 2 reveals that, in addition to blood, human milk is being monitored increasingly. This 241 
shift towards monitoring milk may be attributed to its less invasive nature, greater sample 242 
availability and mass, recent improvements in the sensitivity and accuracy of ultra-trace 243 
analytical techniques (although these are likely still worse than for serum), and the dual role 244 
of human milk as an indicator of both the donor’s body burden, and dietary intake of nursing 245 
infants. Of course, this is offset to some degree by the fact that human milk as a 246 
biomonitoring tool is restricted to a specific sector of the population. Moreover, comparing 247 
Tables 1 and 2, it is apparent that concentrations of PFOS in human blood exceed those in 248 
human milk. Several studies of human milk have been carried out since the first published 249 
reports. Most such studies show detection frequencies (DF) > 90%, except those of 250 
Bernsmann and Fürst (2008) (DF of 66% in Germany), and Guerranti et al. (2013), in which 251 
the detection frequency was below 50% (DF of 41% in Italy). Median concentrations range 252 
from 0.04 to 0.33 ng/mL, except for the study of Roosens et al. (2010) for the Flemish 253 
general population, who reported a median concentration an order of magnitude higher than 254 
other studies (2.9 ng/mL). Some of the samples reported by Roosens et al. (2010) were 255 
collected from donors living near a PFOS production facility, for which the authors also 256 
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reported high concentrations of PFOS in serum. Elevated concentrations of PFOS had also 257 
been reported previously in biota from the same location by Dauwe et al. (2007).  258 
In contrast to blood and milk, only a small number of papers have reported concentrations of 259 
PFASs in other human matrices such as: liver, seminal plasma, and umbilical cord blood 260 
(Apelberg et al., 2007; Guruge et al., 2005; Inoue et al., 2004; Kärrman et al., 2007a; 261 
Kuklenyik et al., 2004; Midasch et al., 2007; Olsen et al., 2003; So et al., 2006). 262 
Scientific understanding of the origins of and influences on the presence of PFOS in humans 263 
is complicated by a number of factors (Lindstrom et al., 2011). Just as environmental 264 
degradation of PFOS precursors constitutes an important indirect source of PFOS 265 
contamination of the ambient environment; external exposure to PFOS precursors followed 266 
by in vivo metabolism, has been identified as a potentially substantial indirect contributor to 267 
human body burdens of PFOS (Trudel et al., 2008; Vestergren et al., 2008). Such indirect 268 
pathways are distinct from direct exposure via human contact with and uptake of PFOS itself. 269 
Moreover, PFOS (as well as other long chain PFASs) tend to accumulate in the human body 270 
with an estimated half-life of around 5 years (Olsen et al., 2007a). This slow elimination from 271 
the human body hampers efforts to determine how changes in lifestyle, diet, or other 272 
exposure-related factors influence blood levels. Notwithstanding this, while age has been 273 
suggested to exert little influence on circulating PFAS concentrations, with inconsistent 274 
results in cross-sectional studies (Haug et al., 2009; Harada et al., 2007), age associations 275 
could be consistent with dietary exposure in a post phase out situation (Nøst et al., 2014). 276 
However, as highlighted above, gender and ethnicity do seem to influence the accumulation 277 
of some compounds. In a recent paper, Kato et al. (2011) attributed differences in human 278 
body burdens between ethnic groups to ethnic differences in exposure related to lifestyle, the 279 
use of products containing PFASs, and diet. Meanwhile, gender-related differences in body 280 
burden (lower concentrations in women than men) have been attributed to physiological 281 
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differences (i.e. accumulation and elimination), as well as pregnancy, lactation and 282 
menstruation (Harada et al., 2004). 283 
 284 
Direct Pathways of Human Exposure to PFOS 285 
Non-occupational exposure to PFOS is thought to occur via the ingestion of food and 286 
drinking water, as well via inhalation and contact with indoor dust. 287 
Drinking water. Data concerning concentrations of PFOS in drinking water are rather limited, 288 
and all published studies report concentrations in the ng/L range (see Table 3). Initially, Saito 289 
et al. (2004) reported PFOS concentrations in tap water from Japan to fall between 0.1 and 290 
12.0 ng/L. Later studies (Lange et al., 2007; Ericson et al., 2009; Skutlarek et al., 2006; 291 
Tanaka et al., 2008) have reported higher concentrations however; up to 58 ng/L and 143 292 
ng/L PFOS in tap water from Spain (Ericson et al., 2009) and Japan (Tanaka et al., 2008) 293 
respectively. Overall, PFOS is one of the most frequently detected PFASs (together with 294 
PFOA) in drinking water, with detection frequencies varying between 40 and 100% in 295 
published papers. Reassuringly, maximum values reported in drinking water to date, fall 296 
below the USEPA’s short term advisory limit concentration for drinking water of 200 ng/L 297 
PFOS. 298 
Indoor air and dust. In addition to drinking water; recent investigations show the indoor 299 
environment is a potentially important contributor to human exposure to PFASs including 300 
PFOS (D'Hollander et al., 2010; Fromme et al., 2009; Goosey and Harrad, 2011; Haug et al., 301 
2011a). The first paper concerning PFOS contamination of indoor dust was published in 302 
2003, by Moriwaki et al. (Table 4). Sixteen samples of house dust were analysed, containing 303 
concentrations of PFOS between 11 and 2,500 ng/g. Since then, similar studies have been 304 
carried out in Canada, Japan, Sweden, USA, Australia, the UK, and Spain, with wide 305 
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variation in concentrations found. While Bjorklund et al. (2009) reported concentrations of 306 
PFOS in dust from 10 houses in Sweden in 2009 to range between 15 and 120 ng/g, Strynar 307 
et al. (2008) and Kato et al. (2009) reported substantially higher concentrations, ranging 308 
between 8.9 and 12,100 ng/g in the USA, and 2.6 and 18,000 ng/g in Australia. Median 309 
concentrations further reflect international variations, being 38 ng/g for the Swedish study, 310 
and 201 ng/g and 480 ng/g for the Canadian and Australian surveys respectively. Moreover, 311 
Goosey and Harrad (2011) also reported statistically significant differences (p<0.05) between 312 
concentrations of PFOS in dust from different countries. Specifically, UK, Australia, Canada, 313 
France, Germany, and US > Kazakhstan; and UK, Australia, Canada, and US > Thailand. 314 
They attributed such differences to lower use of products containing PFAS in Kazahkstan and 315 
Thailand compared to Europe, North America, and Australia. 316 
Moreover, recent studies have reported concentrations of PFOS and other PFAS in indoor air 317 
(principally vapour phase, but with some particulate phase compounds incorporated) (Ericson 318 
Jogsten et al., 2012; Goosey and Harrad, 2012; Shoeib et al., 2011). In these, PFOS was the 319 
most prevalent PFAS, with a wide range of concentrations between countries (for example, 320 
lower values detected in Spain, higher in the UK). The frequency of detection for PFOS in 321 
indoor air is more variable than for dust (in air the range is from 0% to 100% c.f. 60% to 322 
100% for dust). 323 
Outdoor air. Outdoor air has also been studied, sometimes in conjunction with indoor air. 324 
Shoeib et al. (2005) reported PFAS concentrations in outdoor air were 1 or 2 orders of 325 
magnitude lower than in indoor air, as data from more recent studies in Table 5 corroborate. 326 
This is consistent with the hypothesis that substantial indoor sources of PFOS exist, with the 327 
result that indoor air likely exerts an appreciable influence on outdoor atmospheric 328 
contamination. While this would logically lead to higher atmospheric concentrations of PFOS 329 
in conurbations due to higher urban building densities; Barber et al. (2007) reported higher 330 
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detection frequencies of PFAS (including PFOS) than expected in outdoor air from rural 331 
areas. Such findings suggest the environmental distribution of PFAS is complex, and that 332 
indoor environments are not the only driver influencing outdoor contamination. 333 
Diet. Overall, based on the exposure models and reviews published to date (D’Eon and 334 
Mabury 2011; Ericson-Jogsten et al, 2012; Fromme et al., 2009; Trudel et al., 2008; 335 
Vestergren et al., 2008); food contaminated via bioaccumulation, has been suggested by 336 
several authors as the principal pathway of direct human exposure to PFOS; (D'Hollander et 337 
al., 2010; Fromme et al., 2007a; Trudel et al., 2008; Kärrman et al., 2009; Vestergren et al., 338 
2008; Fromme et al., 2009, Herzke et al., 2013). 339 
In 2012, Ericson-Jogsten reported diet as the main pathway of PFOS exposure for adults and 340 
toddlers from Catalonia, Spain (constituting more than 70% of the daily total intake). 341 
Ingestion of water was identified as the second most important human exposure pathway, 342 
with inhalation of air and ingestion of dust considered negligible (< 0.5% of the total intake). 343 
An alternative Scenario-Based Risk Assessment approach (SceBRA) (Scheringer et al., 2001) 344 
was used in the studies of Trudel et al. (2008) and Vestergren et al. (2008). Both studies 345 
reported food ingestion as one of the most important pathways under three different exposure 346 
scenarios, although there was some divergence between the two studies about the absolute 347 
contribution of diet. Moreover, house dust ingestion was identified as a significant direct 348 
exposure pathway in both studies (though different absolute values of its proportional 349 
contribution to overall exposure were reported); while for some other pathways, e.g. direct 350 
hand contact with carpets treated with products containing PFOS and subsequent oral 351 
ingestion, assessment of their importance differs substantially between studies. Future 352 
evaluations of the relative contributions of different pathways to overall exposure to PFOS, 353 
will benefit from recent and on-going improvements in analytical techniques that permit 354 
detection of PFOS in foodstuffs and other exposure matrices at lower levels. 355 
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 356 
Indirect sources of human exposure to PFOS 357 
As highlighted above, POSF-derived substances may be metabolised in vivo to PFOS, 358 
constituting a substantial indirect source of human exposure to PFOS. The POSF-derived 359 
substances in question represent a vast array of structures with the general formula 360 
C8F17SO2NRR’, that are referred to generically as ―PFOS-precursors‖ (or ―PreFOS‖ in some 361 
literature, such as Asher et al., 2012). Consequently, as described by Prevedouros et al. 362 
(2006), and Ross et al. (2012), two general routes of exposure may occur: (1) direct exposure 363 
to PFOS, through diet, inhalation, and contact with contaminated settled dust (either by 364 
ingestion or dermal contact), and (2) exposure to PFOS-precursors, followed by their 365 
biotransformation in the body to PFOS. The main PFOS-precursor substances and its salts are 366 
listed in Table 6. 367 
PFOS-precursors are mainly degraded to PFOS by in vivo metabolic processes (Martin et al., 368 
2010; Xu et al., 2004). Some PFOS-precursors like N-Et-FOSA and N-Et-FOSE, have shown 369 
low conversion factors < 1% in rats and trout (Xu et al., 2004; Tomy et al., 2004) or have not 370 
yet been studied. However, in 2003, Seacat et al. reported a conversion factor to PFOS of up 371 
to 20% in a study where rats were exposed long term to N-Et-FOSE; an observation 372 
confirmed subsequently by Xie et al. (2009). Although the reported levels of PFOS-373 
precursors are generally lower and their physicochemical properties differ from those of 374 
PFOS, a variety of them have been detected in water (Ahrens et al., 2009), in indoor and 375 
outdoor air (Shoeib et al., 2005; Jahnke et al., 2007), in packaged food (Tittlemier et al., 376 
2006), and in live organisms (from mussels to bald eagles) and waterbird eggs (Kannan et al., 377 
2005; Wang et al., 2008). One of the most measured PFOS-precursors is 378 
perfluorooctanesulfonamide (PFOSA), which is a stable intermediate in the pathway of 379 
PFOS-precursor degradation to PFOS, and whose structure is depicted in Fig. 1. 380 
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Perfluorinated sulfonamide based products (PFSAm) are also important, as their production is 381 
associated with the presence of FOSAs and FOSEs as degradation or residual products. 382 
Positive correlations between the concentrations of PFOSA and PFOS have been found in 383 
biological samples (e.g. Martin et al., 2004) suggesting that PFOSA, and maybe other PFOS-384 
precursors, can be important contributors to body burdens of PFOS in animal species (Asher 385 
et al., 2012). 386 
As mentioned above, recent papers have examined the utility of human exposure models to 387 
evaluate the contribution of indirect exposure pathways to human body burdens of PFOS 388 
(Vestergren et al., 2008; D’Eon and Mabury 2011; Fromme et al., 2009; Gebbink et al., 389 
2015). Such studies are still quite limited in number, but their general consensus is that the 390 
significance of indirect sources in driving human body burdens of PFOS should be taken into 391 
account, or even had hitherto been underestimated (e.g. D’Eon and Mabury (2011)). This 392 
becomes even more important in the wake of the 3M phase out, as while direct sources of 393 
PFOS exposure are expected to decrease in the general population, indirect sources stemming 394 
from continued use of PFOS-precursors remain. Vestergren et al. (2008) suggested the 395 
relative contributions of direct and indirect exposure were dependent on the level of 396 
exposure. While under low and intermediate exposure scenarios, direct dietary exposure 397 
appeared the principal pathway, intake of PFOS under a high-end exposure scenario was 398 
dominated by indirect precursor exposure via indoor dust (41-68%), and indoor air (10-19%). 399 
The study of Gebbink et al. (2015) considered comparable pathways of exposure to those 400 
studied by Vestergren et al. However, total exposure in the Gebbink et al study was 1-2 401 
orders of magnitude lower, with indirect exposure to PFOS making higher and lower 402 
contributions to overall exposure under low (11%) and high (33%) exposure scenarios 403 
respectively than estimated previously. Gebbink et al. attributed the differences between their 404 
observations and those of previous studies, to their use of recent data reporting lower levels 405 
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of PFOS and PFOS-precursors in human diet (Ullah et al., 2014). However, other reasons 406 
such as the use of more recently published biotransformation factors describing the 407 
conversion of precursors, as well as the development of more sensitive analytical methods 408 
were identified as causes of the lower exposure estimates. Moreover, D’Eon and Mabury 409 
(2011) critically reviewed the contribution of PFOS precursors to observed body burdens of 410 
PFOS, and suggested that studies to date may underestimate the contribution of such indirect 411 
exposure. This was principally due to the fact that such studies consider indirect exposure to 412 
occur only as a result of exposure to PFOS precursors present as impurities or residual 413 
products from the manufacture of PFOS, but do not include exposure arising from 414 
manufacture and use of the precursors themselves. 415 
In summary, studies to date suggest strongly that indirect exposure to PFOS makes an 416 
important contribution to human body burdens. However, such studies are not yet conclusive. 417 
For example, estimates of the contribution of such exposure varies between 10% and 70% of 418 
the daily intake of PFOS in the studies of Verstergren et al. (2008) and Gebbink et al. (2015) 419 
(based on the three different scenarios) and Fromme et al. (2009). Such variation is 420 
attributable to inherent uncertainties in pivotal parameters such as the estimated efficiency of 421 
precursor metabolism to PFOS. At the current time, efforts must focus on addressing: (1) the 422 
lack of data on the toxicokinetics of various PFOS-precursor compounds in animals, (2) the 423 
difficulty in extrapolating rodent data to humans, and (3) the fact that many commercially 424 
relevant PFOS precursors have yet to be determined in any sample (Martin et al., 2010). 425 
Overall, the uncertainties associated with studies to date, highlight a clear need for alternative 426 
approaches, and a small but growing number of studies suggests that exploitation of the chiral 427 
properties of some PFOS isomers and their precursors may constitute one such approach 428 
(Wang et al., 2009; Liu et al., 2015). 429 
 430 
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Isomer patterns and chirality of PFOS and its precursors – environmental forensic 431 
tools? 432 
Historically, ΣPFOS has been quantified together (see Tables 1 to 5). Recently however, new 433 
approaches (discussed further below) have been have been suggested as biomarkers of 434 
exposure and applied in efforts to differentiate between direct exposure to PFOS and PFOS-435 
precursor exposure (Benskin et al., 2009; Martin et al., 2010). 436 
Isomer profiles. As described above, the processes via which PFOS precursors (i.e. POSF) 437 
are manufactured, are expected to produce about 70% of the linear isomer, with the 438 
remaining 30% made up of a mixture of various branched chain isomers. In contrast, due to 439 
preferential retention of linear PFOS in humans and rats, PFOS isomer profiles in animal 440 
species are expected to comprise <30% branched chain isomers. While this holds true for 441 
species such as fish and gulls for which ≥90% of PFOS is the linear isomer (Asher et al., 442 
2009; Gebbink and Letcher, 2010; Houde et al., 2008) (Table 7); in some human samples, the 443 
proportion of branched chain isomers can be 40-50% (Kärrman et al., 2007b; Zhang et al., 444 
2013; Beesoon et al., 2011, Liu et al., 2015). Moreover, an in vitro study using human 445 
microsomes has showed branched chain PFOSAs to be preferentially metabolised to PFOS 446 
relative to linear PFOSA (Benskin et al., 2009). This provides further evidence that precursor 447 
exposure may account for human PFOS isomer profiles that are enriched in branched chain 448 
isomers. This enriched profile in some human samples has been hypothesised as providing 449 
evidence of precursor exposure. Moreover, observed temporal and within-population 450 
variations in the relative abundance of branched chain PFOS isomers in humans (Kärrman et 451 
al., 2007a; Haug et al., 2009), may be at least partly attributable to concomitant variations in 452 
precursor exposure. In fact, the study of temporal trends by Liu et al. (2015), shows the 453 
percentage of branched isomers in the Swedish population has increased from 32 to 45% 454 
between 1996 and 2010, suggesting that exposure to PFOS precursors is becoming more 455 
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important compared to direct exposure, as predicted by the theoretical models discussed 456 
earlier. 457 
Current evidence to support this hypothesis is not clear-cut however (Ross et al, 2012). While 458 
excretion in rats of branched chain PFOSAs exceeded that of the linear isomer; a 459 
corresponding increase in the relative abundance of the sum of branched chain PFOS isomers 460 
was not observed in the same animals. More detailed analysis of the relative abundance of 461 
individual branched chain isomers in this study suggests a more complex situation. While the 462 
relative abundance in the studied rats of one branched isomer (5m-PFOS), increased relative 463 
to its abundance in a commercial PFOS mixture; that of another (1m-PFOS) decreased (Ross 464 
et al., 2012). This may point to a need to monitor relative abundances of individual branched 465 
chain isomers rather than the sum of all such isomers, to provide more conclusive insights 466 
into the relative contribution of precursor exposure. This conclusion is supported by the study 467 
of Gebbink et al. (2015), where an estimated isomeric pattern of 84% linear PFOS was 468 
calculated for exposure via water, diet, air and dust, that contrasts with isomer patterns 469 
observed in human serum samples (Beesoon et al., 2011; Haug et al., 2009; Benskin et al., 470 
2007; Zhang et al., 2013). The potential feasibility of such a detailed isomer-specific 471 
approach is demonstrated by a study of PFOS isomer distributions in gull eggs from spatially 472 
distinct breeding colonies throughout the Laurentian Great Lakes (Gebbink and Letcher, 473 
2010). In this study, 8 individual branched chain PFOS isomers were detected in gull eggs, 474 
with spatial variations in the contribution of linear PFOS in eggs highlighted as potentially at 475 
least partly attributable to location-specific variations in the PFOS precursor exposure. 476 
Chirality. One feature of many PFOS isomers is chirality, including the environmentally 477 
relevant monomethyl-branched isomers 1m-, 3m-, 4m-, and 5m- PFOS, represented in Fig. 2, 478 
where ―#m-‖ refers to the carbon position of the branched CF3 group (Asher et al., 2012). 479 
Chirality has environmental significance for several reasons. The enantiomers of a chiral 480 
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compound rotate polarised light in opposite directions, but otherwise exhibit identical 481 
physical and chemical properties. Consequently, environmental, physical, and chemical 482 
processes generally affect both enantiomers identically (Kallenborn et al., 2001). However, 483 
different enantiomers can interact differently with other chiral molecules (enzymes or 484 
biological receptors), leading to different biological and toxicological behaviour (Hühnerfuss 485 
et al., 2009). Moreover, unless production of a specific enantiomer is sought, the relative 486 
abundance of each enantiomer, or the enantiomer fraction (EF), (referred to thereafter as the 487 
chiral signature) is equal in commercially-produced chemicals. In such cases, the two 488 
enantiomers (A and B) exist in identical proportions (eq 1) and the chiral signature is said to 489 
be racemic (EF = 0.5). Consequently, observations of chiral signatures that deviate 490 
significantly from racemic in environmental or biological matrices are strong evidence of 491 
biodegradation or metabolism, and provide a powerful tool to enhance understanding of 492 
environmental processes (Lehmler et al., 2010). Specifically, in the context of elucidating the 493 
relative importance of precursor exposure, the EFs of chiral isomers such as 1m-PFOS in 494 
freshly-manufactured PFOS are 0.5. In contrast, a branched chain PFOS precursor (1m-495 
PreFOS) was shown to be metabolised enantioselectively by human liver microsomes (Wang 496 
et al., 2009). As a result, the observation of non-racemic EFs in human serum of 1m-PFOS, 497 
combined with experimental evidence that 1m-PFOS itself is not excreted enantioselectively 498 
in rats (Wang et al., 2011) (see Table 7); represents strong evidence of a discernible influence 499 
of precursor exposure on human body burdens of PFOS. Recently, Liu et al. (2015) have also 500 
found non-racemic EFs in serum samples from Swedish and US population, supporting 501 
previous studies by Wang et al. (2009 and 2011). Furthermore, a significant correlation 502 
between %br-PFOS (i.e. the proportion of PFOS that are branched chain isomers) and 1m-503 
PFOS in samples from 1996-2000 has been also discussed there, but further studies are still 504 
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required in view of the fact that the observed changes in EF can explain only around 40% of 505 
the increment in branched isomers (Liu et al., 2015). 506 
 507 
EF=A/(A+B)      (eq. 1) 508 
 509 
The above are prime examples of how knowledge of chiral signatures of PFOS isomers in 510 
various environmental compartments including those pertinent to human exposure, offer 511 
potentially rich insights into various aspects of the environmental fate and behaviour of PFOS 512 
and its precursors. As well as helping elucidate the relative influence on human body burdens 513 
of direct exposure to PFOS compared to indirect exposure via metabolism of its precursors; 514 
studies of chiral organochlorine compounds indicate wider insights may also be possible. For 515 
example, measurement of the chiral signatures of polychlorinated biphenyls (PCBs) and 516 
organochlorine pesticides in relevant environmental matrices has enhanced understanding of 517 
issues such as: the relative contribution of primary versus secondary sources to outdoor air 518 
(Bidleman et al., 1998; Robson and Harrad, 2004), and the role of volatilisation from soil as a 519 
source of PCBs to grass (Desborough and Harrad, 2011). Moreover, tracking chiral 520 
signatures of PFOS and its precursors could lead to better understanding of toxicological 521 
effects on the human body, as enantioselective toxicity may exist (Loveless et al., 2006). 522 
 523 
Forward look 524 
PFOS is an environmental pollutant which has been widely studied. Significant manufacture 525 
of both PFOS and PFOS precursors continues today; e.g. PFOS production has increased in 526 
China since 2002 (with higher reported levels of PFOS in some regions of China than in the 527 
US, despite the small production volumes in China compared to reported 3M production 528 
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(Olsen et al., 2012)), while PFOS and PFOS-precursors are still being manufactured in 529 
Europe and Asia for certain applications (UNEP, 2010; Paul et al., 2009; Zhang et al., 2013). 530 
This review has highlighted the potential insights into its environmental fate that may be 531 
gained from better knowledge of the isomer and enantiomer-specific behaviour of both PFOS 532 
and its precursors. Despite this, at the current time, only a few papers have been published 533 
reporting the relative abundance of both linear and branched PFOS isomers in the 534 
environment. Even fewer papers have been published that address the chirality of PFOS and 535 
its precursors. In part, this is likely due to the fact that reference standards for branched chain 536 
isomers and individual enantiomers have only recently become available, and to the 537 
challenging nature of existing analytical methods for their measurement, exacerbated by the 538 
usually very low concentrations of individual branched chain isomers in environmental and 539 
biological samples. Moreover, as yet it has only proven possible to resolve the enantiomers of 540 
1m-PFOS. As this represents only 2-3% of total PFOS and ~6-10% of branched chain 541 
isomers (Riddell et al., 2009), there are inherent uncertainties in extrapolating findings for 542 
this one isomer to others. Furthermore, while variations in precursor exposure may explain 543 
variations in PFOS isomer profiles; other factors such as gender and pregnancy may also be 544 
influential. Despite these obstacles, exploiting the chirality and isomer patterns of PFOS and 545 
its precursors offers new opportunities to gain insights into their environmental fate and 546 
behaviour, as exemplified by previous studies of other chiral organohalogens like -547 
hexachlorocyclohexane and PCBs. Given the potential rewards, further development, 548 
validation, and carefully targeted application of analytical methods for the determination of 549 
chiral signatures of PFOS isomers are necessary. They will not be a trivial task; but they 550 
constitute urgent research priorities. 551 
 552 
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Table 1. Comparison of reported PFOS concentrations and ranges in human blood or serum (ng/mL) 
Authors Year Country Matrix n % DF Mean Median
c
 Range 
Ericson et al.  2007 Spain Whole blood 48 100 7.64 7.6 0.76-16.2 
Fromme et al.
 
(b) 2007 Germany Plasma 356 100 13.5 13.7 2.1-55.0 
Hansen et al. 2001 USA Serum 65 100 25.519 25.7 6.7-81.5 
Haug et al.
 
(b) 2011 Norway Serum 41 100 6.9 NR 2.3-15.0 
Hölzer et al. 2008 North Rhine Plasma 80 NR NR 4.3 1.5-26.2 
Jin et al. 2007 China Serum 119 NR NR 22.4 0.2-145.0 
Kannan et al.  2004 USA Serum 46/29
d
 91/93
d
 32.5/32.9
d
 28.9/26.2
d
 <1.3-124 
USA Whole blood 11/19
d
 100/100
d
 66/73.2
d
 81/72
d
 11-164 
USA Plasma 70 100 42.8 42 16-83 
Colombia Whole blood 25/31
d
 100/100
d
 8.0/8.5
d
 7.3/8.1
d
 4.6-14 
Brazil Whole blood 17/10
d
 100/100
d
 10.7/13.5
d
 8.4/12.7
d
 4.3-35 
Italy Serum 8/42
d
 87.5/90.5
d
 4.4/4.3
d
 3.5/4.2
d
 <1-10.3 
Poland Whole blood 15/10
d
 100/100
d
 33.3/55.4
d
 33.8/40.9
d
 16.0-116 
Belgium Plasma 4/16
d
 100/100
d
 11.1/16.8
d
 10.4/17.6
d
 4.5-27.0 
India Serum 11/34
d
 55/50
d
 2.3/1.7
d
 2.5/1.3
d
 <1-3 
Malaysia Whole blood 7/16
d
 100/100
d
 11.7/13.2
d
 12.7/13.1
d
 6.2-18.8 
Korea Whole blood 25/25
d
 100/100
d
 15.1/27.1
d
 11.3/18.3
d
 3.0-92 
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Japan Serum 13/25
d
 100/100
d
 20.1/14.1
d
 18.3/12.4
d
 4.1-40.3 
Kärrman et al
. 
(a) 2006 Sweden Whole blood 66 100 16 17.1 1.7-37.0 
Kärrman et al. (b) 2006 Australia Serum 40 NR 21.3 20.8 12.7-29.5 
Kärrman et al. (a) 2007 Sweden Serum 12 100 20.7 18.7 8.2-48.0 
Kato et al. 
(NHANES reports 
overview). Calafat et 
al. (2007) (a) (b) 
2011 USA Serum (years 99-00) 1562 100 30.4 NR NR 
Serum (years 03-04) 2094 99.9 20.7 NR NR 
Serum (years 05-06) 2120 99.9 17.1 NR NR 
Serum (years 07-08) 2100 99.8 13.2 NR NR 
Midash et al. 2006 Germany Plasma 105 100 NR 22.3 6.2-131.0 
Olsen et al. 2005 USA Serum 178 NR 30.1 29.5 NR 
Plasma 178 NR 33.3 34.7 NR 
Yeung et al. 2006 China Serum 85 NR NR 52.7 NR 
c) For concentrations <LOQ, the value was assumed to = 1/2 LOQ. d) Separate female/male data reported for this study. 
DF: Detection frequency. NR: Not reported. 
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Table 2. Comparison of reported PFOS concentrations and ranges in human breast milk (ng/mL) 
Authors Year Country n % DF Mean Median
c
 Range 
Antignac et al. 2013 France 48 90 0.092 0.075 <0.050-0.330 
Bernsmann and Fürst 2008 Germany 203 66 NR 0.082 0.05-0.284 
Fromme et al. 2010 Germany 201 72 NR 0.040 <0.030-0.110 
Guerranti et al. 2013 Italy 49 41 0.85 NR <1.020-4.280 
Haug et al. (b) 2011 Norway 19 100 0.093 0.087 0.004-0.250 
Kadar et al. 2011 France 30 100 NR 0.074 0.024-0.171 
Kärrman et al. (a) 2007 Sweden 12 100 0.201 0.121 0.063-0.465 
Kärrman et al. 2010 Spain 10 100 0.12 0.110 0.070-0.220 
Kim et al. (b) 2011 Korea 17 100 0.061 NR 0.032-0.130 
Liu et al. 2010 China 24 100 0.046 0.049 0.006-0.137 
Llorca et al. 2010 Spain 20 95 0.071 0.084 0.028-0.865 
Mosch et al. 2010 Germany 20 95 NR 0.049 <0.030-0.195 
Nakata et al. 2007 Japan 51 100 NR NR 0.008-0.401 
Roosens et al. 2010 Belgium 22 NR NR 2.900 <0.400-28.2 
So et al. 2006 China 19 100 0.105 0.100 0.045-0.360 
Sundstrom et al. 2011 Sweden 20
d
 100 0.156 0.206 0.088-0.151 
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Tao et al. 2008 USA 45 96 NR 0.106 <0.032-0.617 
Cambodia 24 100 0.067 0.040 0.017-0.327 
Vietnam 40 100 0.076 0.058 0.017-0.393 
Indonesia 20 100 0.084 0.067 0.025-0.256 
Philippines 24 100 0.098 0.104 0.027-0.208 
Malaysia 13 100 0.121 0.111 0.049-0.350 
India 39 85 0.046 0.039 <0.011-0.120 
Japan 24 100 0.232 0.196 0.140-0.523 
Thomsen et al. 2010 Norway 68 NR NR 0.110 0.028-0.36 
Völkel et al. 2008 Germany 19 100 0.116 0.113 0.028-0.239 
Germany 38 100 0.126 0.123 0.033-0.309 
Hungary 13 100 0.317 0.330 0.096-0.639 
c) For concentrations <LOQ, the value was assumed = 1/2 LOQ. d) 20 pools of human milk. 
DF: Detection frequency. NR: Not reported. 
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Table 3. Comparison of reported PFOS concentrations and ranges (ng/L) in drinking water 
Authors Year Country n % DF A/GM Median
c
 Range 
Ericson et al. 2008 Spain 4 100 0.57
c
 (GM) 0.59 0.39-0.87 
Ericson et al. 2009 Spain 40 87 3.72 (GM) 0.51 <0.12-58.12 
Kim et al.(a) 2011 Korea 15 NR NR NR <0.33-11.00 
Loos et al. 2007 Italy 6 100 8.1 (A) NR 6.20-9.70 
Saito et al. 2004 Japan 30 67 
0.7-12.5
d
 
(GM) 
0.65 <0.10-12.00 
Skutlarek et al. 2006 Germany 37 35 2.09
c
 (GM) 1.00 <1.00-22.00 
Takagi et al. 2008 Japan 26 96 1.51 (GM) 1.90 <0.16-22.00 
Tanaka et al. 2008 Japan NR NR NR NR <0.01-143.0 
c) For concentrations <LOQ, the value was assumed = 1/2 LOQ. b) Estimated in 6 different areas. 
DF: Detection frequency. A: Average. GM: Geometric mean. NR: Not reported. 
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Table 4. Comparison of reported PFOS concentrations and ranges in indoor dust (ng/g) 
Authors Year 
Country/Microenvironment 
Category 
Source n % DF Average Median
c
 Range 
Bjorklund et al. 2009 Sweden / Houses Dust 10 100 49.0
d
 39.0 15-120 
Sweden / Apartments Dust 38 79 175.0
d
 85.0 <8.0-1100 
Sweden / Offices Dust 10 100 144.0
d
 110.0 29-490 
Sweden / Daycare centres Dust 10 100 38.0
d
 31.0 23-65 
Sweden / Cars Dust 5 60 18.0
d
 12.0 <8.0-33 
Ericson Jogsten et al. 2012 Spain / Houses Dust 10 100 2.1 2.2 0.13-12.0 
Goosey and Harrad 2011 UK / Cars Dust 20 100 132.0 97.0 20-1500 
UK / Classrooms Dust 42 100 640.7 980.0 22-3700 
UK / Houses Dust 45 100 144.7 450.0 3.5-7400 
UK / Offices Dust 20 100 182.5 370.0 20-1000 
Australia / Houses Dust 20 100 187.0 170.0 6.5-8100 
Canada / Houses Dust 19 100 157.8 140.0 42-1300 
France / Houses Dust 10 100 193.8 160.0 54-1700 
Germany / Houses Dust 10 100 188.9 170.0 47-1000 
Kazahkstan / Houses Dust 9 80 12.5 59.0 <0.03-130 
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Thailand / Houses Dust 20 100 19.5 16.0 3-130 
USA / Houses Dust 10 100 318.1 310.0 110-930 
Kato et al. 2009 Australia / Houses Dust 39 74 NR 480.0 <2.6-18000 
Kubwabo et al. 2005 Canada / Houses Dust 67 67 443.7 37.8 2.3-5065 
Moriwaki et al. 2003 Japan / Houses Dust 16 100 39.5 25.0 15.0-2500 
Strynar et al. 2008 USA / Houses (102) and child 
daycare centres (10) 
Dust 112 95 761.0 201.0 <8.9-12100 
c) For concentrations <LOQ, the value was assumed = 1/2 LOQ d) Arithmetic mean. 
DF: Detection frequency. NR: Not reported. 
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Table 5. Comparison of reported PFOS concentrations and ranges in indoor and outdoor air (pg/m
3
) 
Authors Year Country Source n % DF Mean Median
c
 Range 
Barber et al. 2007 Norway Indoor air 4 0 NR NR <47.4 
Ericson Jogsten et al. 2012 Spain Indoor air 10 33 0.3 0.1 <0.13-67.0 
Goosey and Harrad 2012 UK Indoor air 20 90 12.4 11.5 <1.0-400.0 
UK Indoor air 12 100 49.4 55.0 12.0-89.0 
Shoeib et al. 2011 Canada Indoor air 39 0 <LOD <LOD <LOD 
Barber et al. 2007 UK Outdoor air 2 NR NR NR 46 
UK Outdoor air 10 NR NR NR 1.6 
Dreyer et al. 2009 Germany Outdoor air 117 0 <LOD <LOD <LOD 
Germany Outdoor air 121 0 <LOD <LOD <LOD 
Genualdi et al. 
2010 
Diff. 
Countries 
Outdoor air 20 50 NR NR 2.03-149.5 
Goosey and Harrad 2012 UK Outdoor air 10 70 1.5 1.6 <0.1-6.1 
Shoeib et al. 2011 Canada Outdoor air 6 0 <LOD <LOD <LOD 
c) For concentrations <LOQ, the value was assumed = 1/2 LOQ. 
DF: Detection frequency. NR: Not reported. 
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Table 6. List of PFOS, its salts and its main precursors 
CAS number Common name Systematic name 
Molecular 
formula 
N/A PFOS anion 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-1-Octanesulfonate C8F17SO3
-
 
1763-23-1 
PFOS acid 
(perfluorooctanesulfonic 
acid) 
1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-1-Octanesulfonic acid C8F17SO3H 
2795-39-3 PFOS potassium (K
+
) salt 
1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-1-Octanesulfonic acid, 
potassium salt 
C8F17SO3K 
29081-56-9 PFOS ammonium (NH4
+
) salt 
1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-1-Octanesulfonic acid, 
ammonium salt 
C8F17SO3NH4 
29457-72-5 PFOS lithium (Li
+
) salt 
1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-1-Octanesulfonic acid, 
lithium salt 
C8F17SO3Li 
70225-14-8 
PFOS diethanolamine (DEA) 
salt 
1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-1-Octanesulfonic 
acid,compd. with 2,2-iminobis[ethanol] (1:1) 
C8F17SO3NH 
(CH2CH2OH)2 
307-35-7 POSF 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-1-Octanesulfonyl fluoride C8F18O2S 
1691-99-2 N-EtFOSE alcohol 
N-ethyl-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-N-(2-hydroxyethyl)-
1-Octanesulfonamide 
C12H10F17NO3S 
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4151-50-2 N-EtFOSA 
N-ethyl-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-1-
Octanesulfonamide 
C10H6F17NO2S 
24448-09-7 N-MeFOSE alcohol 
1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-N-(2-hydroxyethyl)-N-
methyl-1-Octanesulfonamide 
C11H8F17NO3S 
31506-32-8 N-MeFOSA 
1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluoro-N-methyl-1-
Octanesulfonamide 
C9H4F17NO2S 
25268-77-3 N-MeFOSEA 
2-Propenoic acid, 2-[[(heptadecafluorooctyl)sulfonyl]methylamino]ethyl 
ester 
C14H10F17NO4S 
423-82-5 N-EtFOSEA 2-Propenoic acid, 2-[ethyl[(heptadecafluorooctyl)sulfonyl]amino]ethyl ester C15H12F17NO4S 
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Table 7. Linear versus branched chain composition profiles and enantiomer fractions (EFs) of PFOS and its precursors in various matrices 
Authors Year Country Study Matrix n Analytes 
Asher et al. 2012 Canada Lake Aquatic Species 67 PFOSA (≈57% linear) 
      PFOS (>90% linear) 
    Water 2 PFOS (70% linear) 
       Sediment 3 PFOS (>90% linear) 
Beesoon et al. 2011 Canada Human Dust 18 PFOS (≈70% linear) 
    Serum 20 PFOS (≈64% linear) 
    Cord serum 20 PFOS (≈54% linear) 
Benskin et al. 2007 Canada Human Serum 14 PFOS (≈80% linear) 
Haug et al. 2009 Norway Human Serum 57 PFOS (53-78 linear) 
Houde et al. 2008 Canada Niagara/Lake Fish 22 PFOS (88-93% linear) 
    Water NR PFOS (43-56 linear) 
Kärrman et al. (b) 2007 Sweden Human Serum/blood 17 PFOS (68% linear) 
  UK   13 PFOS (59% linear) 
  Australia   40 PFOS (59% linear) 
Ross et al. 2012 Canada Animals Blood 8 PFOSA (≈78% linear) 
    Blood 8 PFOS (≈77% linear) 
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    Heart 8 PFOSA (≈93% linear) 
    Fat 8 PFOSA (≈86% linear) 
Sharpe et al. 2010 Canada - Fish NR PFOS (>70% linear) 
Wang et al. 2011 Canada Animals Rats 3 1m-PFOS (EF≈0.5) 
   Human Serum 8 1m-PFOS (EF=0.43 ) 
     Human Serum 7 1m-PFOS (EF=0.35-0.43 ) 
Zhang et al. 2013 China Human Serum 129 PFOS (48% linear) 
NR: Not reported. 
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Fig. 1. PFOS K salt, PFOSA, and POSF structures 
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Fig 2. Linear PFOS structure (named as n-PFOS) and monomethylated PFOS branched isomers, where the chiral carbon is represented by *. Each isomer 
containing a chiral centre has 2 enantiomers (R and S) 
 
